Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 6/20 | 0.39 |
| ▸ | HRH1 | P35367 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GPR4 | P46093 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100888 | 0.93 | HTR2A (0.42) | HTR2AHTR1ADRD2HRH2HRH1 | |
| SCHEMBL5715420 | 0.89 | TP53 (0.49) | HTR2AHTR1ADRD2HRH2HRH1 | |
| SCHEMBL5713860 | 0.87 | TP53 (0.42) | TP53GPR4 | |
| SCHEMBL5715462 | 0.85 | HTR2A (0.38) | HTR2AHTR1ADRD2HRH2HRH1 | |
| SCHEMBL5715250 | 0.84 | KDM4E (0.44) | HRH2HRH1THRB | |
| SCHEMBL5714137 | 0.84 | TP53 (0.39) | HTR2AHTR1ADRD2HRH2HRH1 | |
| SCHEMBL5715351 | 0.84 | CYP3A4 (0.45) | HTR2AHRH2HRH1TP53GPR4 | |
| SCHEMBL5714103 | 0.84 | ALDH1A1 (0.39) | HTR1ATP53HTR1DHTR1B | |
| SCHEMBL5714956 | 0.84 | TP53 (0.54) | TP53THRB | |
| SCHEMBL5714867 | 0.83 | SIGMAR1 (0.44) | HTR2ADRD2HRH2HRH1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006527212-A | — | — | 2006-11-30 | — | — | JP | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | HTR2A 1618/4885HTR1A 2790/4885DRD2 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.